Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Enanta Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -96.9%. For fiscal 2025 it was -125.4%, against -171.6% the year before. The highest annual figure on record is 72.1% in fiscal 2014.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -125.4% | +46.2 |
| FY2024 | Sep 30, 2024 | -171.6% | −2.6 |
| FY2023 | Sep 30, 2023 | -169.0% | −27.6 |
| FY2022 | Sep 30, 2022 | -141.3% | −59.9 |
| FY2021 | Sep 30, 2021 | -81.4% | −51.8 |
| FY2020 | Sep 30, 2020 | -29.5% | −52.1 |
| FY2019 | Sep 30, 2019 | 22.6% | −12.2 |
| FY2018 | Sep 30, 2018 | 34.8% | +17.6 |
| FY2017 | Sep 30, 2017 | 17.2% | −7.3 |
| FY2016 | Sep 30, 2016 | 24.5% | −24.6 |
| FY2015 | Sep 30, 2015 | 49.1% | −23.0 |
| FY2014 | Sep 30, 2014 | 72.1% | +42.1 |
| FY2013 | Sep 30, 2013 | 30.0% | −21.3 |
| FY2012 | Sep 30, 2012 | 51.3% | −4.3 |
| FY2011 | Sep 30, 2011 | 55.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -135.8% | −4.4 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -76.3% | +121.0 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -64.1% | +61.9 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -123.6% | +59.1 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -131.4% | +54.1 |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -197.3% | −48.9 |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -126.1% | +80.7 |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -182.7% | +28.9 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -185.6% | −62.7 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -148.5% | −18.8 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -206.8% | −44.0 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -211.6% | −32.1 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -122.9% | −14.0 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -129.7% | −25.3 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -162.7% | −51.6 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -179.5% | −70.0 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -108.9% | −82.7 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -104.3% | +19.8 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -111.1% | −34.6 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -109.5% | −87.8 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -26.2% | −51.8 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -124.2% | −142.1 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -76.5% | −92.3 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -21.7% | −32.2 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | 25.6% | −11.6 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | 17.9% | −22.9 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | 15.9% | −19.6 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | 10.5% | −18.0 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | 37.2% | +6.5 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | 40.8% | −7.3 |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | 35.4% | +147.6 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | 28.5% | +88.7 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | 30.7% | +78.5 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | 48.1% | +62.1 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -112.2% | −104.5 |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -60.2% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -47.8% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -14.0% | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -7.7% | – |
See a number that looks wrong?